(Total Views: 221)
Posted On: 01/06/2023 3:34:00 PM
Post# of 271
NetworkNewsBreaks – MetAlert Inc. (MLRT) Featured in Research Reports
MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in two recent reports published by Ludlow Research. In both reports, Ludlow issued an upgrade research opinion on MetAlert with a valuation target of $1.00 to $1.25 per share. The upgrades were based on various factors, including MetAlert’s agreement with a major IoT connectivity company out of Germany, its expansion of medical devices for the aging and autism markets, ramp-up in SmartSole unit production to fulfill backorders, as well as elimination of toxic debt. “In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet, which should now provide increased stability to their public float. The influx of new chips in Q4 2022 should significantly increase production of SmartSole units in early 2023. This ramp-up in production should help fulfill backorders currently in place and increase revenues in the coming months,” reads the latest update. “The elimination of toxic debt, improved guidance to their NFC operations, and launch of new medical devices geared towards the geriatric and autism health care markets now places the company in a much healthier position going forward into 2023.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in two recent reports published by Ludlow Research. In both reports, Ludlow issued an upgrade research opinion on MetAlert with a valuation target of $1.00 to $1.25 per share. The upgrades were based on various factors, including MetAlert’s agreement with a major IoT connectivity company out of Germany, its expansion of medical devices for the aging and autism markets, ramp-up in SmartSole unit production to fulfill backorders, as well as elimination of toxic debt. “In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet, which should now provide increased stability to their public float. The influx of new chips in Q4 2022 should significantly increase production of SmartSole units in early 2023. This ramp-up in production should help fulfill backorders currently in place and increase revenues in the coming months,” reads the latest update. “The elimination of toxic debt, improved guidance to their NFC operations, and launch of new medical devices geared towards the geriatric and autism health care markets now places the company in a much healthier position going forward into 2023.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
